Comparative study of natural autoantibodies in the serum and cerebrospinal fluid of normal individuals and patients with multiple sclerosis and other neurological diseases

Matsiota, P.; Blancher, Antoine; Doyon, Bernard; Guilbert, B; Clanet, M.; Kouvelas, Elias D.; Avraméas, Stratis

doi:10.1016/0769-2625(88)90134-1

Cited by 41 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, MS patients also have higher levels of natural autoantibodies in their CSF compared to both patients with other neurological diseases and healthy controls (Matsiota et al, 1988). Organ-specific IgM autoantibodies to liver, heart, kidney and brain have been detected in sera of both normal individuals, and patients with MS (Daar and Fabre, 1981).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis

Peterson

Tsunoda

Masaki

et al. 2007

Journal of Neuroimmunology

View full text Add to dashboard Cite

Two myelin oligodendrocyte glycoprotein ) monoclonal antibodies (mAbs) were produced from an A.SW mouse with progressive experimental autoimmune encephalomyelitis. Polyreactivity/specificity of the mAbs was demonstrated by ELISA. Functionality and a potential role in pathogenesis of systemic autoimmunity were demonstrated in vitro in a lymphocytotoxicity assay and in vivo upon injection into naïve mice. Injection of MOG mAb producing hybridomas into naïve mice resulted in immunoglobulin deposition in kidneys and liver. This model will be useful in determining whether transitional forms between CNS (organ)-specific and systemic autoimmune diseases exist, and whether progressive multiple sclerosis has features of a systemic autoimmune disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Interestingly, MS patients have higher levels of natural autoantibodies in their CSF compared to patients with other neurological diseases and healthy controls (Matsiota et al, 1988).…”

Section: Introductionmentioning

confidence: 99%

Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis

Peterson

Tsunoda

Masaki

et al. 2007

Journal of Neuroimmunology

View full text Add to dashboard Cite

show abstract

“…Polyreactive natural antibodies purified from intravenous immunoglobulins (IVIg) have been demonstrated to decrease the inflammatory response as well as disease severity in rats with MBP induced EAE (Bruley-Rosset et al, 2003). Interestingly, MS patients have been found to have higher levels of natural autoantibodies in their CSF compared to both healthy controls and patients with other neurological diseases (Matsiota et al, 1988). We have produced two MOG 92-106 reactive natural antibodies from an A.SW mouse with progressive-EAE that also recognize gangliosides GM1, GM3 and GD1b by enzyme linked immunosorbent assay (ELISA), which suggests that antibodies against myelin may be capable of exerting a more direct effect in neuroprotection or neurodegeneration (Peterson et al, in submission).…”

Section: Can Inflammation Protect Against Neurodegenerationmentioning

confidence: 99%

Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis

Peterson¹,

Fujinami²

2007

Journal of Neuroimmunology

168

104

View full text Add to dashboard Cite

Although axonal loss has been observed in demyelinated multiple sclerosis (MS) lesions, there has been a major focus on understanding mechanisms of demyelination. However, identification of markers for axonal damage and development of new imaging techniques has enabled detection of subtle changes in axonal pathology and revived interest in the neurodegenerative component of MS. Axonal loss is generally accepted as the main determinant of permanent clinical disability. However, the role of axonal loss early in disease or during relapsing-remitting disease is still under investigation, as are the interactions and interdependency between inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of MS.

show abstract

“…According to Matsiota et al, 21 MS patients have elevated antibody titers against PRL and numerous other antigens, relative to two other groups (Table 1). Grinsted et al 22 observe significantly higher concentrations of PRL, luteinizing hormone (LH), follicle stimulating hormone (FSH), and both total and free testosterone; but lower levels of oestrone sulfate, in the serum of 14 female MS patients of reproductive age, relative to controls.…”

Section: Cross-sectional Studiesmentioning

confidence: 99%

Prolactin in multiple sclerosis

et al. 2012

View full text Add to dashboard Cite

Multiple sclerosis (MS) is more common among women than men. MS often goes into remission during pregnancy, when prolactin (PRL) levels are known to be high. In an animal model of demyelination, PRL promoted myelin repair, suggesting it has potential as a remyelinating therapy in MS. In this systematic review, we examined the known associations between PRL and MS, in order to elucidate its potential role in the pathophysiology and treatment of MS. A systematic search was performed in the electronic databases PubMed and EMBASE, using the keywords "prolactin" AND "multiple sclerosis." The inclusion criteria were met by 23 studies. These studies suggested to us that elevated PRL may be more common in MS patients than in controls. Hyperprolactinemia may also be associated with clinical relapse in MS, especially among patients with hypothalamic lesions or optic neuritis; however, it is unknown if this is a cause or consequence of a relapse. Overall, most people with MS have normal PRL levels. The impact of PRL on MS outcomes remains unclear.

show abstract

Comparative study of natural autoantibodies in the serum and cerebrospinal fluid of normal individuals and patients with multiple sclerosis and other neurological diseases

Cited by 41 publications

References 23 publications

Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis

Polyreactive myelin oligodendrocyte glycoprotein antibodies: Implications for systemic autoimmunity in progressive experimental autoimmune encephalomyelitis

Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis

Prolactin in multiple sclerosis

Contact Info

Product

Resources

About